Filter posts

Perspective on Market Valuation for Biotech Drug Developers

Of the 300 publicly traded U.S. biotechs, 219 (73%) are developing drugs. The other 27% …

Biotech IPO Window - Still Ajar?

IPO plans for Quark Pharmaceuticals were officially put on hold last week as markets continue …

Biotech IPO Update for May 18th, 2011

There are now eight biotech IPOs for 2011, bringing the total for the recent US …

Nasdaq Biotech Index re-ranking for next Monday

Twice a year, in May and November, the NASDAQ OMX Group re-ranks the closely watched …

IPO Update - April 5th, 2011

The six biotech IPOs of 2011 have followed 2010’s IPO trends; all took significant haircuts getting …

The BTK buyout

Remember this BTK post we wrote back  in February of 2010?  Well, we thought it was time …

BIO Europe Spring - State of the Biotech Industry

BIO Industry Analysis provided opening remarks at BIO Europe Spring in Milan, Italy, this morning.  …

Anitbody Deals Peaked in 2007

Antibody and antibody-like scaffold molecules have been on the pharma licensing radar for some time. …

2011, The Year of Positive Thinking? BIO/IPREO Study Reveals High Hopes for the Industry

BIO CEO’s closing plenary session featured plenty of crystal ball gazing and candid quips about …

Release of BIO/Biomedtracker Drug Approval Rates Study

BIO and BioMedTracker are pleased to present the findings of their joint clinical trial success …